Neurobehavioral correlates of chronic hepatitis C

Journal of Psychopathology and Behavioral Assessment

Volumn 26, Issue 3, 2004, Pages 203-210

  Hilsabeck, Robin C ^a   Malek Ahmadi, Parviz ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anxiety; Cognitive dysfunction; Depression; Fatigue; HCV

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE; INTERFERON; MODAFINIL; RIBAVIRIN;

ANXIETY DISORDER; BLOOD TRANSFUSION; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEPRESSION; DRUG USE; FATIGUE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; NEUROLOGICAL COMPLICATION; PATIENT EDUCATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SUICIDE; SYMPTOM; UNITED STATES; VIRUS LOAD;

EID: 3543013152     PISSN: 08822689     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOBA.0000022113.60976.4a     Document Type: Review

References (65)

1. Afonso, A. M., Jiang, J., Penin, F., Tareau, C., Samuel, D., Petit, M. A., et al. (1999). Non-random distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. Journal of Virology, 73, 9213-9221.
2. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., et al. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341, 556-562.
3. Armstrong, G. L., Alter, M. J., McQuillan, G. M., & Margolis, H. S. (2000). The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology, 31, 777-782.
4. Backmund, M., Meyer, K., von Zielonka, M., & Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34, 188-193.
5. Barkuizen, A., Rosen, H. R., Wolf, S., Flora, K., Benner, K., & Bennett, R. M. (1999). Musculoskeletal pain and fatigue are associated with chronic hepatitis C. American Journal of Gastroenterology, 94, 1355-1360.
6. Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M., & Ware, J. E. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7, 39-55.
7. Blumenfeld, H. (2002). Neuroanatomy through clinical cases. Sunderland, MA: Sinauer Associates.
8. Bonkovsky, H. L., Woolley, J. M., & The Consensus Interferon Study Group. (1999). Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264-270.
9. Borson, S., McDonald, G. J., Gayle, T., Deffebach, M., Lakshinarayan, S., & Van Tuinen C. (1992). Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics, 33, 1990-2001.
10. Cawthorne, C. H., Rudat, K. R., Burton, M. S., Brown, K. E., Luxon, B. A., Janney, C. G., et al. (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 91, 149-155.
11. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244, 359-362.
12. Costa, M. A., & Schiff, E. R. (1999). Hepatitis C. Current Treatment Options in Gastroenterology, 2, 481-489.
13. Davis, G. L., & Rodrigue, J. R. (2001). Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine, 345, 215-217.
14. Dinan, T. G. (1994). Glucocorticoids and the genesis of depressive illness. A psychobiological model. British Journal of Psychiatry, 164, 365-371.
15. Dwight, M. M., Kowdley, K. V., Russo, J. E., Ciechanowski, P. S., Larson, A. M., & Katon, W. J. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychosomatic Research, 49, 311-317.
16. El-Serag, H. B., Kunik, M., Richardson, P., & Rabeneck, L. (2002). Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 123, 476-482.
17. Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136, 288-292.
18. Fattovich, G., Giustina, G., Favarato, S., & Ruol, A. (1996). A survey of adverse events in 11242 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology, 24, 38-47.
19. Fontana, R. J., Hussain, K. B., Schwartz, S. M., Moyer, C. A., Su, G. L., & Lok, A. S. F. (2002). Emotional distress in chronic hepatitis C patients not receiving anti-viral therapy. Journal of Hepatology, 36, 401-407.
20. Fontana, R. J., Moyer, C. A., Sonnad, S., Lok, A. S. F., Sneed-Pee, N., Walsh, J., et al. (2001). Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. American Journal of Gastroenterology, 96, 170-177.
21. Forton, D. M., Allsop, J. M., Main, J., Foster, G. R., Thomas, H. C., & Taylor-Robinson, S. D. (2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet, 58, 38-39.
22. Forton, D. M., Taylor-Robinson, S. D., & Thomas, H. C. (2002). Reduced quality of life in hepatitis C - Is it all in the head? Journal of Hepatology, 36, 435-438.
23. Forton, D. M., Thomas, H. C., Murphy, C. A., Allsop, J. M., Foster, G. R., Main, J., et al. (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 35, 433-439.
24. Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209-212.
25. Gershon, A. S., Margulies, M., Gorczynski, R. M., & Heathcote, E. J. (2000). Serum cytokine values and fatigue in chronic hepatitis C infection. Journal of Viral Hepatitis, 7, 397-402.
26. Gleason, O. C., Yates, W. R., Isbell, M. D., & Philipsen, M. A. (2002). An open-label trial of citalopram for major depression in patients with hepatitis C. Journal of Clinical Psychiatry, 63, 194-198.
27. Goulding, C., O'Connell, P., & Murray, F. E. (2001). Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection; relationship to RT-PCR status and mode of acquisition. European Journal of Gastroenterology and Hepatology, 13, 507-511.
28. Grant, I., Prigatano, G. P., Heaton, R. K., McSweeny, A. J., Wright, E. C., & Adams, K. M. (1987). Progressive neuropsychologic impairments and hypoxemia: relationship in chronic obstructive pulmonary disease. Archives of General Psychiatry, 44, 999-1006.
29. Hilsabeck, R. C., Hassanein, T. I., Carlson, M. D., Ziegler, E. A., & Perry, W. (2003). Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. Journal of the International Neuropsychological Society, 9, 847-854.
30. Hilsabeck, R. C., Perry, W., & Hassanein, T. I. (2002). Neuropsychological impairment in patients with chronic hepatitis C. Hepatology, 35, 440-446.
31. Hoofnagle, J. H. (1997). Hepatitis C: The clinical spectrum of disease. Hepatology, 26, 15S-20S.
32. Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M. (2003). Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: A prospective study. General Hospital Psychiatry, 25, 34-38.
33. Hosoda, S., Takimura, H., Shibayama, M., Kanamura, H., Ikeda, K., & Kumada, H. (2000). Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry and Clinical Neurosciences, 54, 565-572.
34. Hurlock, E. C. (2001). Interferons: Potential roles in affect. Medical Hypotheses, 56, 558-566.
35. Johnson, M. E., Fisher, D. G., Fenaughty, A., & Theno, S. A. (1998). Hepatitis C virus and depression in drug users. American Journal of Gastroenterology, 93, 785-789.
36. Jones, E. A. (1999). Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet, 354, 397.
37. Kenny-Walsh, E. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. New England Journal of Medicine, 340, 1228-1233.
38. Kraus, M. R., Schäfer, A., Csef, H., Faller, H., Mork, H., & Scheurlen, M. (2001). Compliance with therapy in patients with chronic hepatitis C: Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Digestive Diseases and Sciences, 46, 2060-2065.
39. Kraus, M. R., Schäfer, A., Csef, H., Scheurlen, M., & Faller, H. (2000). Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics, 41, 377-384.
40. Kronfol, Z., & Remick, D. G. (2000). Cytokines and the brain: Implications for clinical psychiatry. American Journal of Psychiatry, 157, 683-694.
41. Lauer, G. M., & Walker, B. D. (2001). Hepatitis C virus infection. New England Journal of Medicine, 345, 41-52.
42. Lee, D. H., Jamal, H., Regenstein, F. G., & Perrillo, R. P. (1997). Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Digestive Diseases and Sciences, 42, 186-191.
43. Lustman, P. J., Freedland, K. E., Griffith, L. S., & Clouse, R. E. (1998). Predicting response to cognitive behavior therapy of depression in type 2 diabetes. General Hospital Psychiatry, 20, 302-306.
44. Maes, M. (1999). Major depression and activation of the inflammatory response system. Advances in Experimental Medicine and Biology, 461, 25-46.
45. Malek-Ahmadi, P. (2001). Mood disorders associated with interferon treatment: Theoretical and practical considerations. The Annals of Pharmacotherapy, 35, 489-495.
46. Markowitz, J. C., Klerman, G. L., Clougherty, K. F., Spielman, L. A., Jacobsberg, L. B., Fishman, B., et al. (1995). Individual psychotherapies for depressed HIV-positive patients. American Journal of Psychiatry, 152, 1504-1509.
47. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339, 1485-1492.
48. McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., et al. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123, 1061-1069.
49. Meyerhoff, D. J., Bloomer, C., Cardenas, V., Norman, D., Weiner, M. W., & Fein, G. (1999). Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology, 52, 995-1003.
50. Monji, A., Yoshida, I., Tashiro, K., Hayashi, Y., & Tashiro, N. (1998). A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics, 39, 562-564.
51. Muir, A. J., & Provenzale, D. (2002). A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. Journal of Clinical Gastroenterology, 34, 268-271.
52. National Institutes of Health. (1997). Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology, 26, 2S-10S.
53. Ormel, J., Oldehinkel, T., Brilman, E., & Van Den Brink, W. (1993). Outcome of depression and anxiety in primary care: A three wave 31/2 year study of psychopathology and disability. Archives of General Psychiatry, 50, 759-766.
54. Peluso, R., Haase, A., Stowring, L., Edwards, M., & Ventura, P. (1985). A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology, 147, 231-236.
55. Peterson, P. K., Hu, S., Salak-Johnson, J., Molitor, T. W., & Chao, C. C. (1997). Differential production of and migratory response to beta chemokines by human microglia and astrocytes. Journal of Infectious Disease, 175, 478-481.
56. Piche, T., Gelsi, E., Schneider, S. M., Hebuterne, X., Giudicelli, J., Ferrua, B., et al. (2002). Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut, 51, 434-439.
57. Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., et al. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37, 443-51.
58. Spiegel, D., Morrow, G. R., Classen, C., Raubertas, R., Stott, P. B., Mudaliar, N., et al. (1999). Group psychotherapy for recently diagnosed breast cancer patients: A multicenter feasibility study. Psycho-Oncology, 8, 482-493.
59. Sullivan, M., Katon, W., Russo, J., Dobie, R., & Sakai C. (1993). A randomized trial of nortriptyline for severe chronic tinnitus: Effects on depression, disability, and tinnitus symptoms. Archives of Internal Medicine, 153, 2251-2259.
60. Sullivan, M. D., La Croix, A. Z., Baum, C., Grothaus, L. C., & Katon, W. K. (1997). Functional status in coronary artery disease: A one year prospective study of the role of anxiety and depression. American Journal of Medicine, 103, 348-356.
61. Van Thiel, D. H., Friedlander, L., de Maria, N., Molloy, P. J., Kania, R. J., & Colantoni, A. (1998). Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepato- Gastroenterology, 45, 328-330.
62. Walker, E. A., Gelfand, M. D., Gelfand, A. N., Creed, F., & Katon, W. J. (1996). The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. General Hospital Psychiatry, 18, 220-229.
63. Wessely, S., & Pariante, C. (2002). Fatigue, depression and chronic hepatitis C infection. Psychological Medicine, 32, 1-10.
64. White, D. A., Heaton, R. K., Monsch, A. U., & The HNRC Group. (1995). Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. Journal of the International Neuropsychological Society, 1, 304-315.
65. Zdilar, D., Franco-Bronson, K., Buchler, N., Locala, J. A., & Younossi, Z. M. (2000). Hepatitis C, interferon alfa, and depression. Hepatology, 31, 1207-1211.